科研之友
微信
新浪微博
Facebook
分享链接
摘要
2010 was not a year of survival breakthroughs in hematologic malignancies. However, in Hodgkin's disease and multiple myeloma new therapies emerged as the standard of care and nilotinib may be considered the treatment choice for newly diagnosed chronic myeloid leukemia.
- 出版日期2011-2
